Robert Stoltz, Director of Clinical Research Studies, Georgia Retina. However, those patients with dry AMD have not been so lucky. “Over the last decade, we have seen many new therapies come to market for patients with wet AMD.

We take special care to ensure that our study patients experience the best medical care possible. We partner with the National Eye Institute, some of the nation’s top pharmaceutical companies, and other clinical practices to explore the causes and cures for many retinal conditions. Georgia Retina has a long history of commitment to and participation in clinical trials to provide our patients access to new, state-of-the-art preventative, or therapeutic treatments.

and five million people worldwide (source 1,2). GA is a leading cause of blindness that impacts more than one million people in the U.S. ATLANTA-( BUSINESS WIRE)- Georgia Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy (GA).